CT/MRI Co-Registration Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2005 by University Health Network, Toronto.
Recruitment status was Active, not recruiting

Sponsor:

Collaborator:

Princess Margaret Hospital, Canada

Information provided by:

University Health Network, Toronto

ClinicalTrials.gov Identifier:

NCT00252460

First received: November 9, 2005

Last updated: NA

Last verified: October 2005

History: No changes posted

Purpose

The target volume in prostate cancer radiotherapy typically consists of the entire prostate gland which is localized by contours drawn on axial computed tomography (CT) radiation planning images. Compared with CT, magnetic resonance (MR) can provide better definition of the prostate gland with respect to the surrounding tissues and the use of multi-plannar reconstruction avoids the problem of partial volume averaging inherent in CT. CT has been shown to significantly overestimate the volume of the gland using the MR-defined prostate volume as the gold standard. Co-registration of MR and CT datasets, matched on fixed bony landmarks, has enabled radiation planning using a MR-defined clinical target volumes, combined with CT-based electron density information necessary for radiation treatment planning.

Rationale and Hypothesis:

Co-registration may allow better delineation of tumour volumes in prostate cancer. This investigation is a fesibility study designed to evaluate and optimize imaging parameters and co-registration techniques for CT planning and MRI Simulator.

Condition	Intervention	Phase
Prostatic Neoplasm	Device: Computed Tomography Scan and Magnetic Resonance Imaging	Phase 1


Study Type:	Observational
Study Design:	Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional
Official Title:	Evaluation of Planning Computed Tomography Scan and Magnetic Resonance Imaging Simulator Scan Co-Registration for Delineation of Gross Tumour Volume in Radiotherapy Treatment of Localized Prostate Cancer

Resource links provided by NLM:

MedlinePlus related topics: CT Scans Cancer MRI Scans Nuclear Scans Prostate Cancer

U.S. FDA Resources

Further study details as provided by University Health Network, Toronto:


Estimated Enrollment:	30
Study Start Date:	November 2003

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Histological confirmation of Prostate Adenocarcinoma
Undergoing RT with fiducial markers, IMRT or Escalated Dose Conformal RT

Exclusion Criteria:

Contraindication for MRI

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00252460

Locations


Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9

Sponsors and Collaborators

University Health Network, Toronto

Princess Margaret Hospital, Canada

Investigators


Principal Investigator:	Andrew Bayley, MD	Princess Margaret Hospital, Canada

More Information

No publications provided


ClinicalTrials.gov Identifier:	NCT00252460 History of Changes
Other Study ID Numbers:	UHN REB 03-0601-CE
Study First Received:	November 9, 2005
Last Updated:	November 9, 2005
Health Authority:	Canada: Ethics Review Committee

Additional relevant MeSH terms:


Prostatic Neoplasms Genital Diseases, Male Genital Neoplasms, Male Neoplasms	Neoplasms by Site Prostatic Diseases Urogenital Neoplasms

ClinicalTrials.gov processed this record on February 25, 2015

To Top